Medstar Health Research Institute
The goal of this clinical trial is to learn if adding platelet-rich plasma (PRP) injections near the clitoris improves sexual function more than PRP injections in the vaginal wall alone. The study includes sexually active adults who were assigned female at birth. PRP is made from a person's own blood. It contains growth factors that may help tissue heal and renew. The main questions it aims to answer are: Does adding PRP near the clitoris improve sexual function 6 weeks after treatment, compared with vaginal wall PRP alone? Do any improvements last at 3 and 6 months? How painful are the injections, and what side effects do participants have? Researchers will compare two groups. All participants will get PRP injected into the front wall of the vagina. One group will also get PRP injected near the clitoris. The other group will get a placebo (sham) injection near the clitoris: the needle goes under the skin, but nothing is injected. Participants will not know which group they are in. Participants will: Answer questionnaires about their health and sexual function before treatment. Come to one in-person visit, about 1 hour long. At this visit they will have blood drawn to make the PRP and receive the injections. Rate their pain shortly after the injections. Complete 3 short online follow-up visits at 6 weeks, 3 months, and 6 months. At these visits they will answer questionnaires about sexual function and side effects.
\*\*Background and Rationale\*\* Female sexual dysfunction (FSD) affects approximately 43% of women in the United States, and 23% report associated distress. Non-hormonal treatment options are limited. Platelet-rich plasma (PRP) is an autologous concentrate of platelets. On activation, platelets release growth factors, including vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF). These factors are hypothesized to promote angiogenesis, collagen synthesis, and neural regeneration in target tissues. The Vaginal Injection of Platelet-Rich Plasma (VIP) trial was a…
Inclusion Criteria: * Adults 18 years of age or older who were assigned female at birth * Sexually active, with at least one episode of sexual activity (alone or with a partner) in the past month * English speaking * Able to complete study questionnaires * Willing to undergo blood draw and genital injection procedure Exclusion Criteria: * Pregnant, suspected pregnancy, or breastfeeding/lactating * Active infection * Autoimmune condition * History of pelvic radiation * History of pelvic malignancy * Current use of anticoagulant medication * Prior urogenital platelet-rich plasma injection * H…
A single treatment session. 40-60 mL of autologous whole blood is processed with the Arthrex Angel system (15-minute centrifugation), yielding approximately 2-4 mL of leukocyte-rich platelet-rich plasma (PRP), which is used within 2 hours of preparation. After topical anesthesia, all participants receive two-thirds of the PRP volume injected superficially into the distal anterior vaginal wall, approximately 3 cm from the urethral meatus, using a 28-32 gauge needle. Experimental arm: The remaining PRP (approximately 1 mL) is delivered as two superficial injections of about 0.5 mL each near the junction of the clitoris, clitoral hood, and frenulum. Sham comparator arm: A needle is inserted at the same peri-clitoral sites without injecting any substance. Participants are blinded to peri-clitoral assignment.